NRx Pharmaceuticals, Inc. (NRXP) — Financial statements
Income statement, balance sheet, and cash flow for NRx Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.65↑12860.0% | 0.01↑0.0% | 0.01↑25.0% | 0.00↑100.0% | 0.00 | |
| Gross Profit | 0.58↑11640.0% | -0.01↑0.0% | -0.01↓25.0% | -0.00↓100.0% | -0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 4↓39.1% | 6↓53.6% | 13↓21.5% | 17↓15.9% | 20 | |
| General & Administrative Expenses | 13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 13↓3.3% | 14↓5.0% | 14↓48.0% | 27↓63.6% | 75 | |
| Other Expenses | -0.07 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 17↓14.9% | 20↓28.6% | 28↓37.8% | 44↓53.4% | 95 | |
| Total Costs & Expenses | 17↓11.6% | 20↓28.6% | 28↓37.8% | 44↓53.4% | 95 | |
| Operating Results | ||||||
| Operating Income | -16↑17.7% | -20↑28.6% | -28↑37.8% | -44↑53.4% | -95 | |
| Depreciation & Amortization | 0.14↑2760.0% | 0.01↑0.0% | 0.01↑25.0% | 0.00↑100.0% | 0.00 | |
| EBITDA | -16↑33.3% | -24↑19.9% | -30↑24.5% | -40↑57.3% | -93 | |
| EBIT | -16↑32.7% | -24↑19.9% | -30↑24.5% | -40↑57.3% | -93 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.66↑36.3% | -1↓376.7% | 0.37↑50.2% | 0.25↑1484.7% | -0.02 | |
| Interest Income | 0.01↓72.7% | 0.04↓91.1% | 0.49↑98.4% | 0.25↑1383233.3% | 0.00 | |
| Interest Expense | 0.67↓37.8% | 1↑799.2% | 0.12 | 0.00↓100.0% | 0.02 | |
| Non-Operating Income | 12↑170.0% | 4↑77.8% | 2↑153.3% | -5↓112.5% | -2 | |
| Other Income / Expenses | -12↓128.7% | -5↓111.5% | -3↓155.9% | 5↑114.3% | 2 | |
| Income Before Tax | -29↓13.9% | -25↑16.7% | -30↑24.2% | -40↑57.3% | -93 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -29↓13.9% | -25↑16.7% | -30↑24.2% | -40↑57.3% | -93 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -29↓13.9% | -25↑16.7% | -30↑24.2% | -40↑57.3% | -93 | |
| Bottom-Line Net Income | -29↓13.9% | -25↑16.7% | -30↑24.1% | -40↑88.6% | -349 | |
| EPS (Basic) | -1.34↑43.9% | -2.39↑39.9% | -3.98↓563.3% | -0.60↑91.9% | -7.44 | |
| EPS (Diluted) | -1.34↑43.9% | -2.39↑39.9% | -3.98↓563.3% | -0.60↑91.9% | -7.44 | |
| Weighted Average Shares | 21↑103.5% | 11↑38.8% | 8↓88.5% | 66↑40.2% | 47 | |
| Weighted Average Diluted Shares | 21↑103.5% | 11↑38.8% | 8↓88.5% | 66↑40.2% | 47 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.